神经肿瘤学在美国临床肿瘤学会2022年年会。

IF 2.4 Q2 CLINICAL NEUROLOGY Neuro-oncology practice Pub Date : 2022-12-01 DOI:10.1093/nop/npac071

Rimas V Lukas, Steven J Chmura, Ian F Parney, Aaron Mammoser, Sonali M Smith, Jing Li

{"title":"神经肿瘤学在美国临床肿瘤学会2022年年会。","authors":"Rimas V Lukas, Steven J Chmura, Ian F Parney, Aaron Mammoser, Sonali M Smith, Jing Li","doi":"10.1093/nop/npac071","DOIUrl":null,"url":null,"abstract":"In the following brief report, we highlight the advances in the neuro-oncology space from the ASCO 2022 Annual Meeting. We put into context the phase 2 and 3 trials and how these may alter the standard of care going forward. In addition, we highlight some other earlier work that will lead to future and potentially practice-changing trials.","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"9 6","pages":"552-558"},"PeriodicalIF":2.4000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665054/pdf/npac071.pdf","citationCount":"1","resultStr":"{\"title\":\"Neuro-oncology at the American Society for Clinical Oncology 2022 Annual Meeting.\",\"authors\":\"Rimas V Lukas, Steven J Chmura, Ian F Parney, Aaron Mammoser, Sonali M Smith, Jing Li\",\"doi\":\"10.1093/nop/npac071\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In the following brief report, we highlight the advances in the neuro-oncology space from the ASCO 2022 Annual Meeting. We put into context the phase 2 and 3 trials and how these may alter the standard of care going forward. In addition, we highlight some other earlier work that will lead to future and potentially practice-changing trials.\",\"PeriodicalId\":19234,\"journal\":{\"name\":\"Neuro-oncology practice\",\"volume\":\"9 6\",\"pages\":\"552-558\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665054/pdf/npac071.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuro-oncology practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/nop/npac071\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/nop/npac071","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 1

摘要

在下面的简短报告中，我们将重点介绍ASCO 2022年年会在神经肿瘤学领域的进展。我们将第二阶段和第三阶段的试验以及这些试验可能如何改变未来的护理标准纳入背景。此外，我们强调了其他一些早期的工作，这些工作将导致未来和潜在的实践改变试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Neuro-oncology at the American Society for Clinical Oncology 2022 Annual Meeting.

In the following brief report, we highlight the advances in the neuro-oncology space from the ASCO 2022 Annual Meeting. We put into context the phase 2 and 3 trials and how these may alter the standard of care going forward. In addition, we highlight some other earlier work that will lead to future and potentially practice-changing trials.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Neuro-oncology practice CLINICAL NEUROLOGY-

CiteScore

5.30

自引率

11.10%

发文量

期刊介绍： Neuro-Oncology Practice focuses on the clinical aspects of the subspecialty for practicing clinicians and healthcare specialists from a variety of disciplines including physicians, nurses, physical/occupational therapists, neuropsychologists, and palliative care specialists, who have focused their careers on clinical patient care and who want to apply the latest treatment advances to their practice. These include: Applying new trial results to improve standards of patient care Translating scientific advances such as tumor molecular profiling and advanced imaging into clinical treatment decision making and personalized brain tumor therapies Raising awareness of basic, translational and clinical research in areas of symptom management, survivorship, neurocognitive function, end of life issues and caregiving

期刊最新文献

Reviewer List for the year 2024. Should we be testing for germline and "actionable" mutations in all glioma patients? Foreword. Role of the tumor board when prescribing mutant isocitrate dehydrogenase inhibitors to patients with isocitrate dehydrogenase-mutant glioma. Financial challenges of being on long-term, high-cost medications.